ArticleProbiotics and antimicrobial proteins2026
Biocontrol Potential of Bacillus Amyloliquefaciens JDF-1 Against Aspergillus Flavus During Cigar Tobacco Fermentation: Antifungal Activity, Aflatoxin Suppression, and Metabolomic Associations.
Article in Probiotics and antimicrobial proteins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mould contamination during cigar tobacco fermentation can cause spoilage and aflatoxin accumulation. This study isolated culturable fungi associated with mouldy cigar tobacco and evaluated Bacillus amyloliquefaciens JDF-1 as a candidate biocontrol strain under controlled fermentation conditions. A total of 215 fungal isolates were obtained using six culture media and identified by colony morphology and ITS sequencing. Antagonistic bacteria isolated from healthy tobacco leaves were screened by dual-culture assays and identified using physiological-biochemical characteristics and 16 S rRNA gene sequencing. Candidate compounds tentatively assigned from the cell-free JDF-1 fermentation supernatant were evaluated in a comparative antifungal screening assay against Aspergillus flavus. Four treatments-sterile-water control (CK), JDF-1 inoculation (TA), A. flavus inoculation (TH), and co-inoculation with JDF-1 and A. flavus (THA)-were compared after 35 days of simulated fermentation. (A) flavus was the predominant culturable fungal species, accounting for 48.84% (105/215) of all isolates. JDF-1 produced the largest inhibition zone (9.5 mm) among the screened bacterial isolates and was preliminarily identified as (B) amyloliquefaciens. Among the tested candidate compounds, cyclo(Leu-Pro) showed the lowest EC₅₀ against A. flavus (101.66 ± 6.55 µg/mL), but its contribution to the activity of the native supernatant was not established. The TH treatment showed pronounced mould development and the highest concentrations of aflatoxins B1, B2, G1, and G2. Co-inoculation with JDF-1 substantially reduced visible mould development and aflatoxin accumulation relative to TH, whereas TA showed a mould incidence of 0.71% and no detectable aflatoxins. JDF-1-containing treatments were also associated with changes in major tobacco chemical constituents and metabolite profiles. Untargeted metabolomics and KEGG enrichment identified treatment-associated LC-MS features and pathway annotations but did not establish pathway regulation, metabolic flux, or causal mechanisms. These findings support JDF-1 as a candidate biocontrol strain for reducing A. flavus contamination and aflatoxin risk during cigar tobacco fermentation under controlled conditions. Further targeted metabolite validation, fungal-biomass quantification, and pilot-scale evaluation are required.
Indexed as
Identifiers
42776411What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.